Drug Database
UR

urokinase (Breokinase / Alphakinase / Thrombolase)

✓ Approved

Mitsubishi Tanabe Pharma Corporation · PLAU

什么是 urokinase?

urokinase 是一种治疗药物,由Mitsubishi Tanabe Pharma Corporation研发。该药已获批,用于治疗相关适应症。

药物档案

商品名Breokinase, Alphakinase, Thrombolase
公司Mitsubishi Tanabe Pharma Corporation
分子靶点PLAU
状态Approved

作用机制

分子靶点

urokinase 作用于 1 个分子靶点:

PLAUplasminogen activator, urokinase (URK, UPA)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

urokinase 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersPulmonary thrombosis✓ Approved

相关研究文献

PubMedLife sciences2026-11-19

PLAUR-associated pro-apoptotic responses to inflammatory BV2-derived sEV-enriched preparations: Implications for traumatic brain injury.

Luo Xiangying X, Lan Song S, Fan Fan F, Sun Zhongyi Z et al.

Traumatic brain injury (TBI) causes secondary neuronal loss, but the contribution of microglia-derived small extracellular vesicles (sEVs) remains unclear. We investigated whether sEV-enriched preparations from inflammatory microglial cells promote pro-apoptotic responses in cortical neuronal cultures and assessed the involvement of Plaur, which encodes the cell-surface urokinase-type plasminogen activator receptor (uPAR/CD87). We used a controlled cortical impact mouse model, reanalyzed the cortical stab-wound single-cell RNA-sequencing dataset GSE226207, and characterized sEV-enriched preparations isolated from lipopolysaccharide-stimulated BV2 cells using nanoparticle tracking analysis, transmission electron microscopy, and western blotting. Cortical neuronal cultures were exposed to these preparations and evaluated by TUNEL staining, immunoblotting, bulk RNA sequencing, and siRNA-mediated Plaur knockdown. Controlled cortical impact was associated with neurological impairment, neuronal apoptosis, and microglial/macrophage activation. The public dataset showed injury-associated transcriptional changes and predicted altered microglia-neuron communication. In vitro, BV2-derived sEV-enriched preparations increased TUNEL positivity, increased Bax, caspase-3, and PARP levels, decreased Bcl-2 levels, and induced apoptosis-related transcriptional programs, including Plaur upregulation. Plaur knockdown attenuated these molecular changes. These findings support PLAUR-associated signaling as a candidate mediator of pro-apoptotic responses induced by inflammatory BV2-derived sEV-enriched preparations in vitro. Further in vivo validation is required to establish a causal role for endogenous microglial sEVs after TBI.

PMID 43057416
阅读全文 →
PubMedFrontiers in medicine2026-11-19

Adjunctive intra-arterial thrombolysis with endovascular thrombectomy for acute large-vessel occlusion stroke: a network meta-analysis of randomized trials.

Ma Junqi J, Li Ruige R, Lu Chenfei C, Wang Jinping J et al.

While endovascular thrombectomy (EVT) is standard care for acute ischemic stroke due to large vessel occlusion (AIS-LVO), but nearly half of patients with successful reperfusion do not achieve functional independence. Adjunctive intra-arterial thrombolysis (IAT) aims to address residual distal thrombi and microcirculatory impairment; however, the efficacy and safety of IAT in comparison with other thrombolytics remain uncertain. We conducted a network meta-analysis (NMA) of randomized controlled trials (RCTs) comparing EVT alone vs. EVT combined with IAT using alteplase (ALT), tenecteplase (TNK), or urokinase (UK) in AIS-LVO patients. Primary outcomes were excellent clinical outcome (mRS 0-1) and functional independence (mRS 0-2) at 90 days. Safety outcomes included symptomatic intracranial hemorrhage (sICH) and all-cause mortality. Eight RCTs involving 2,564 patients were included. For excellent clinical (mRS 0-1), EVT + IA-ALT ranked highest [surface under the cumulative ranking curve (SUCRA) 96.2%], followed by EVT + IA-TNK (59.8%). Both showed significant benefits over EVT alone [EVT + IA-TNK vs. EVT: RR 1.20, 95% CI 1.05-1.39. EVT + IA-ALT vs. EVT: RR 1.40, 95% CI 1.21-1.63 and EVT + IA-TNK (0.125 mg/kg) vs. EVT: RR 1.54, 95% CI 1.07-2.20. EVT + IA-ALT (0.225 mg/kg) vs. EVT: RR 1.40, 95% CI 1.21-1.63]. For functional independence (mRS 0-2), EVT + IA-ALT also ranked highest, but no combination strategy showed a statistically significant benefit over EVT alone in pairwise comparisons. Regarding safety, point estimates for sICH risk did not differ significantly between combination strategies and EVT alone. However, EVT + IA-TNK demonstrated a statistically significant advantage over EVT + IA-ALT in terms of lower all-cause mortality (RR 1.58, 95% CI 1.01-2.46). EVT + IA-ALT and EVT + IA-TNK may improve excellent clinical outcome without a statistically significant increase in sICH; however, clinically important bleeding risk cannot be excluded. In exploratory indirect comparisons, EVT + IA-TNK was associated with lower all-cause mortality than EVT + IA-ALT, although this finding is based on sparse evidence and should be interpreted with caution. PROSPERO CRD420261465567.

PMID 43054172
阅读全文 →
PubMedCureus2026-11-18

Biomarkers for Prediction of Cardiovascular Complications in Hip Fracture Surgery in the Elderly.

Avgerinos Konstantinos K, Konstantas Orestis O, Roustemis Anastasios G AG, Karampikas Vasileios V et al.

To evaluate and synthesize evidence on the prognostic value of circulating biomarkers - B-type natriuretic peptide (BNP)/N-terminal pro-BNP (NT-proBNP), troponins T and I, C-reactive protein (CRP), and soluble urokinase plasminogen activator receptor (suPAR) - for short- and long-term mortality in elderly patients undergoing hip fracture surgery, we hypothesized that elevated biomarker levels reflect frailty and underlying cardiac and non-cardiac pathology and predict mortality. We conducted a narrative review of clinical studies in geriatric hip fracture cohorts reporting preoperative and/or postoperative measurements of these biomarkers, extracting study design, timing of sampling, biomarker thresholds, associations with all-cause and cardiovascular mortality, and whether analyses adjusted for age, comorbidity, and surgical factors. Multiple studies report postoperative troponin elevations linked to worse long-term prognosis and higher mortality. BNP and NT-proBNP consistently correlate with cardiovascular risk and increased mortality when measured preoperatively or early postoperatively, with several studies describing nonlinear relationships and threshold effects. CRP shows variable association with mortality, often reflecting infection or systemic inflammatory burden, and composite ratios (e.g., CRP-to-albumin ratio, CRP-to-lymphocyte ratio) may improve prognostic performance. suPAR is associated with multimorbidity and premature death in general populations; data specific to hip fracture patients are limited but suggest higher suPAR quartiles relate to increased 30-day mortality. Heterogeneity in timing of sampling, biomarker thresholds, and statistical adjustments across studies limits definitive recommendations. Overall, BNP/NT-proBNP, troponins, CRP, and suPAR show promise for risk stratification in hip fracture patients, but prospective standardized studies are needed to define optimal markers, timing, and clinical utility.

PMID 43048163
阅读全文 →
PubMedCerebrovascular diseases (Basel, Switzerland)2026-11-15

The minimally invasive soft channel brain hemorrhage evacuation for acute basal ganglia hemorrhage - small hemorrhage evacuation (MIRACLE-S) trial: rationale, design and progress.

Wang Xia X, Zeng Jun-Fa JF, Luo Lei L, Bian Hetao H et al.

Acute spontaneous intracerebral hemorrhage (ICH) is a devastating type of stroke, where patients with small and large hematomas usually make excellent and poor outcomes, respectively, regardless of treatment. However, for patients with a moderate hematoma volume (20-30 mL) in a deep hemispheric location, there is clinical equipoise as to the benefit of any surgical intervention, as the randomized evidence is limited. The minimally invasive soft-channel brain hemorrhage evacuation for acute basal ganglia hemorrhage - small hemorrhage evacuation (MIRACLE-S) trial is a multicenter, prospective, randomized, open-label, blinded-endpoint assessed trial conducted in China. Eligibility criteria are adult patients aged 18 to 80 years with spontaneous basal ganglionic ICH with a hematoma volume of 20 to 30 mL, Glasgow coma scale score 9 to 14, premorbid modified Rankin scale score 0 to 1, and systolic blood pressure <140 mmHg enrolled within 48 hours of symptom onset. Patients are randomized (1:1) to soft-channel minimally invasive surgery (scMIS; stereotactic aspiration with catheter-based urokinase thrombolysis) or guideline-based conservative medical management. The primary efficacy outcome is a hierarchical composite endpoint of death, disability (mRS scores 3 to 5), rehospitalization, and poor health-related quality of life assessed at 180 days and analyzed using a win-ratio approach. Safety outcomes include mortality, rebleeding (including puncture-tract hemorrhage), and infection within 30 days. Recruitment started January 1, 2025. As of January 10, 2026, 148 patients have been randomized at 34 active sites. The required sample size of 420 to detect a win-ratio effect size of 1.62 (P_tie=0.05) should be achieved in 2028. MIRACLE-S will clarify whether aspiration-based scMIS improves recovery as compared with best medical management in patients moderate-volume basal ganglionic ICH, which is a common clinical burden in China and other regions with high rates of ICH. ClinicalTrials.gov Identifier: NCT06688162.

PMID 43033154
阅读全文 →
PubMedJournal of clinical medicine2026-11-14

Pediatric Pleural Empyema: Disease Complexity, Contemporary Management, and Future Research Priorities.

Tarditi Gabriele G, Pisa Camilla Maria CM, Ricci Ilaria I, Civino Raffaella R et al.

Background: Pediatric pleural empyema remains a major complication of community-acquired pneumonia despite vaccination and advances in minimally invasive treatment. This narrative review summarizes current evidence on etiology and microbiology, diagnosis and imaging, antimicrobial therapy, supportive care, pleural drainage, fibrinolysis, surgery, complications, and short- and long-term outcomes. Methods: This structured narrative review searched PubMed from inception through 30 July 2026. No formal risk-of-bias assessment was performed. Of 42 publications assessed in full, 38 were included in the narrative synthesis. Results: Streptococcus pneumoniae, particularly serotype 3, Staphylococcus aureus, and Streptococcus pyogenes remain the principal pathogens. Chest ultrasound is preferred for characterizing pleural collections and guiding intervention, whereas computed tomography is reserved for atypical disease or suspected complications. Small pediatric comparative trials report broadly similar outcomes for catheter drainage with fibrinolysis and video-assisted thoracoscopic surgery (VATS), but differences in sample size, eligibility, treatment protocols, and outcome definitions limit conclusions about comparative effectiveness. Image-guided small-bore catheter drainage with protocol-based urokinase or tissue plasminogen activator is effective for many loculated effusions. Pediatric evidence does not support routine addition of DNase. Comparative trials show broadly similar clinical outcomes for fibrinolysis and video-assisted thoracoscopic surgery, although heterogeneous protocols and limited sample sizes preclude identification of a universally superior strategy. Thoracotomy is rarely required. Conclusions: Management should integrate respiratory and septic severity, pleural anatomy, microbiology, adequacy of drainage, clinical trajectory, and local expertise rather than rely on rigid staging. Long-term recovery is excellent in most previously healthy children receiving timely treatment. Standardized definitions, pediatric outcome sets, multicenter comparative trials, validated predictors of treatment failure, and studies of antimicrobial duration remain important research priorities.

PMID 43030349
阅读全文 →
PubMedBMC neurology2026-11-12

Efficacy and safety of urokinase intravenous thrombolysis in minor stroke according to large vessel occlusion status: a subgroup analysis of the TRUST trial.

Tao Yongli Y, Fang Hui H, Zhou Yifang Y, Gao Yuan Y et al.

The risk-benefit profile of thrombolytic therapy in minor stroke patients with large vessel occlusion (LVO) remains uncertain. This post hoc analysis of the TRUST trial (ThRombolysis with Urokinase for minor Stroke Trial) sought to comparatively assess whether the presence of large vessel occlusion (LVO) modifies the efficacy and safety of urokinase intravenous thrombolysis, compared with best medical treatment(BMT), in patients with minor stroke. This post-hoc exploratory analysis included patients from the TRUST trial with available vascular imaging data, categorized in the LVO and the non-LVO group. Each group was further divided into the UK thrombolysis group and the BMT group. Primary efficacy outcome was the proportion of patients achieving a modified Rankin Scale (mRS) score of 0-1 at 90 days. Safety outcomes included symptomatic intracranial hemorrhage (sICH) within 36 h and all-cause mortality within 90 days. Of the 999 patients enrolled in the TRUST trial, 605 were included in the current study. UK thrombolysis was not associated with a 90-day excellent functional outcome in minor stroke patients, either in LVO patients (adjusted risk ratio [RR] 1.90, 95% CI 0.63-2.26) or in non-LVO patients (adjusted RR 1.02, 95% CI 0.84-1.23) compared with the BMT group (p for interaction = 0.41). In the LVO group, UK thrombolysis showed a non-significant trend toward reduced mortality (adjusted RR 0.04, 95% CI 0.01-1.65), whereas no such effect was observed in non-LVO patients (adjusted RR 0.52, 95% CI 0.11-2.52). No significant interaction was found between groups (p for interaction = 0.25). In addition, there were no patients who experienced sICH in subgroup analysis. This subgroup analysis found no improvement in 90-day functional outcomes with UK thrombolysis in minor stroke patients, irrespective of LVO presence, while maintaining a comparable safety profile with regard to mortality and sICH. The TRUST trial was registered with ClinicalTrials. gov (NCT04420351). Registration Date: June 04, 2020.

PMID 43015686
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多urokinase